Abstract
Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in spleen volume and constitutional symptoms. Maximizing SVR and TSS is critical for MF patients, as both are associated with improved quality of life (QoL) and overall survival (OS). Navtemadlin is a potent, selective, oral MDM2 inhibitor that restores p53 activity, inducing apoptosis of malignant TP53 wild-type (TP53
WT
) CD34
+
MF progenitor cells. In vitro and clinical data demonstrated navtemadlin's synergy with ruxolitinib and disease-modifying potential. POIESIS is a global, randomized, double-blind phase III trial (NCT06479135) evaluating navtemadlin versus placebo as add-on to ruxolitinib in JAK inhibitor-naïve TP53
WT
MF patients with suboptimal response to ruxolitinib. The study includes a ruxolitinib monotherapy run-in period, followed by randomization of suboptimal responders to add-on navtemadlin or placebo to their stable ruxolitinib dose. Study objectives are to isolate the contribution of add-on navtemadlin by assessing SVR and TSS 24-weeks after randomization from the pre-randomization baseline and to demonstrate that this contribution is clinically meaningful using established SVR and TSS endpoints from the pre-ruxolitinib treatment baseline. Secondary endpoints include progression-free survival, leukemia-free survival, and OS.
Clinical Trial Registration: NCT06479135 (ClinicalTrials.gov); EUCT 2023-504724-25-00 (EUClinicalTrials.EU).
Myelofibrosis (MF) is a rare blood cancer that affects the bone marrow, causing scarring (fibrosis) and impairing healthy blood cell production. This leads to symptoms, such as fatigue, pain, night-sweats, and an enlarged spleen. Ruxolitinib, a Janus kinase inhibitor (JAKi), is a standard treatment that can reduce spleen size and improve symptoms. However, many MF patients do not respond optimally to ruxolitinib alone, known as a suboptimal response, and continue to experience persistent symptoms and an enlarged spleen. In these cases, adding a new treatment may provide further clinical benefit.
Navtemadlin is an investigational treatment that inhibits MDM2, a protein which is overproduced in MF cancer cells. MDM2 blocks the activity of another protein, p53, a tumor suppressor that normally helps remove abnormal cells. By blocking MDM2, navtemadlin restores the ability of p53 to eliminate MF cancer cells.
The POIESIS study is a global phase III clinical trial testing whether adding navtemadlin to ruxolitinib improves outcomes in MF patients with a suboptimal response to ruxolitinib alone. POIESIS has two treatment periods. During the first period, patients receive ruxolitinib alone for 18-24 weeks. If their response is suboptimal, patients may be eligible to join the second period, where they are randomly assigned to receive either add-on navtemadlin (Arm 1) or placebo (Arm 2) while continuing ruxolitinib. Navtemadlin efficacy will be assessed by measuring the rates of spleen volume reduction (by MRI/CT scan) and total symptom score improvement (using a daily 7-symptom questionnaire), in each arm, 24 weeks after randomization.